These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 36251300)

  • 1. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
    Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
    JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
    Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
    JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
    JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
    Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
    Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donanemab in Early Alzheimer's Disease.
    Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
    N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
    Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
    JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
    Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
    Fleisher AS; Munsie LM; Perahia DGS; Andersen SW; Higgins IA; Hauck PM; Lo AC; Sims JR; Brys M; Mintun M;
    Neurology; 2024 Mar; 102(5):e208061. PubMed ID: 38386949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Wang J; Shcherbinin S; Sims JR; Chigutsa E
    Alzheimers Dement (N Y); 2023; 9(2):e12404. PubMed ID: 37388759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
    Edwards AL; Collins JA; Junge C; Kordasiewicz H; Mignon L; Wu S; Li Y; Lin L; DuBois J; Hutchison RM; Ziogas N; Shulman M; Martarello L; Graham D; Lane R; Budd Haeberlein S; Beaver J
    JAMA Neurol; 2023 Dec; 80(12):1344-1352. PubMed ID: 37902726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Still grasping at straws: donanemab in Alzheimer's disease.
    Doggrell SA
    Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How donanemab data address the coverage with evidence development questions.
    Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
    Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
    Teng E; Manser PT; Pickthorn K; Brunstein F; Blendstrup M; Sanabria Bohorquez S; Wildsmith KR; Toth B; Dolton M; Ramakrishnan V; Bobbala A; Sikkes SAM; Ward M; Fuji RN; Kerchner GA;
    JAMA Neurol; 2022 Aug; 79(8):758-767. PubMed ID: 35696185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.
    Sperling R; Henley D; Aisen PS; Raman R; Donohue MC; Ernstrom K; Rafii MS; Streffer J; Shi Y; Karcher K; Raghavan N; Tymofyeyev Y; Bogert J; Brashear HR; Novak G; Thipphawong J; Saad ZS; Kolb H; Rofael H; Sanga P; Romano G
    JAMA Neurol; 2021 Mar; 78(3):293-301. PubMed ID: 33464300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
    Ross EL; Weinberg MS; Arnold SE
    JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
    Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
    JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
    Wessels AM; Dennehy EB; Dowsett SA; Dickson SP; Hendrix SB
    Neurol Clin Pract; 2023 Apr; 13(2):e200127. PubMed ID: 36891463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
    Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
    Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.